Clinical Trials
Overview
4 clinical trials. 146 treated breast cancer patients.
80% or greater reduction in metastatic breast cancer recurrence rate over 5 years of follow-up compared to 20-50% reduction in recurrence rate by other approved products.
Peak immune response at 6 months.
No reported serious adverse events attributable to treatment.
Well tolerated safety profile.
Thus far, the safety and efficacy of the GLSI-100 immunotherapy have been tested in four clinical trials, where 146 patients have received treatment. The past trials consist of three Phase I clinical trials and one Phase IIb clinical trial.
Flamingo-01 Phase III Clinical Trial
The current, ongoing trial is a Phase III clinical trial registered with the name, Flamingo-01, and the identifier, NCT05232916. Greenwich LifeSciences is selecting and activating clinical sites from university-based hospitals and cooperative networks in the U.S. and Europe, and patients are being recruited and screened.
Flamingo-01 Phase III Clinical Trial
The current trial is a Phase III clinical trial registered with the name, Flamingo-01, and the identifier, NCT05232916. Greenwich LifeSciences is selecting and activating clinical sites from university-based hospitals and cooperative networks in the U.S. and Europe, and patients are being recruited and screened.